BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20680968)

  • 21. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology.
    Aladjidi N; Auvrignon A; Leblanc T; Perel Y; Bénard A; Bordigoni P; Gandemer V; Thuret I; Dalle JH; Piguet C; Pautard B; Baruchel A; Leverger G;
    J Clin Oncol; 2003 Dec; 21(23):4377-85. PubMed ID: 14645428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia.
    Girmenia C; Micozzi A; Piciocchi A; Gentile G; Di Caprio L; Nasso D; Minotti C; Capria S; Cartoni C; Alimena G; Meloni G; Amadori S; Foà R; Venditti A
    Leuk Res; 2014 Apr; 38(4):469-74. PubMed ID: 24534569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
    Creutzig U; Ritter J; Heyen P; Berthold F; Henze G; Kabisch H; Lampert F; Niethammer D; Riehm H; Schellong G
    Klin Padiatr; 1992; 204(4):236-45. PubMed ID: 1518259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
    Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
    Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Risk factors for invasive fungal infections during intensive chemotherapy of acute leukemia--retrospective study].
    Zupanić-Krmek D; Nemet D; Mrsić M; Bogdanić V; Labar B; Jandrlić M; Kalenić S
    Acta Med Croatica; 2004; 58(4):275-84. PubMed ID: 15700683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.
    Gamis AS; Howells WB; DeSwarte-Wallace J; Feusner JH; Buckley JD; Woods WG
    J Clin Oncol; 2000 May; 18(9):1845-55. PubMed ID: 10784625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors.
    Wiley JM; Smith N; Leventhal BG; Graham ML; Strauss LC; Hurwitz CA; Modlin J; Mellits D; Baumgardner R; Corden BJ
    J Clin Oncol; 1990 Feb; 8(2):280-6. PubMed ID: 2299371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
    de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
    Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
    Ehlers S; Herbst C; Zimmermann M; Scharn N; Germeshausen M; von Neuhoff N; Zwaan CM; Reinhardt K; Hollink IH; Klusmann JH; Lehrnbecher T; Roettgers S; Stary J; Dworzak M; Welte K; Creutzig U; Reinhardt D
    J Clin Oncol; 2010 May; 28(15):2591-7. PubMed ID: 20406937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.
    Yilmaz S; Oren H; Demircioğlu F; Irken G
    Pediatr Hematol Oncol; 2008; 25(3):195-204. PubMed ID: 18432502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.